Department of Radiation Oncology, St. Jude Children's Hospital, Memphis, United States.
Department of Radiation Oncology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, United States.
Radiother Oncol. 2019 May;134:89-95. doi: 10.1016/j.radonc.2019.01.026. Epub 2019 Feb 5.
The use of radiotherapy (RT) for pediatric patients with Hodgkin lymphoma (HL) experiencing disease progression or recurrence (15%) is controversial. We report treatment patterns and outcomes for pediatric patients with refractory/recurrent HL (rrHL) treated with curative-intent RT.
Forty-six patients with rrHL treated with salvage RT at our institution were identified. All received risk-adapted, response-based frontline therapy and were retrieved with cytoreductive regimens followed by RT to failure sites, with or without autologous hematopoietic cell transplantation (AHCT). Cumulative incidence (CIN) of local failure (LF) and survival were estimated after salvage RT and regression models determined predictors of LF after salvage RT.
RT was administered as part of frontline therapy in 70% of patients, omitted for early response assessment in 13%, or deferred for primary progression in 17%. AHCT was omitted in 20% of patients. Median initial and salvage dose/site were 25.5 Gy and 30.6 Gy, respectively. Eight patients experienced progression. Two died without progression (median follow-up from salvage RT = 3.8 years). The 5-year CIN of LF after salvage RT was 17.7% (95% confidence interval [CI], 8.2-30.2%). The 5-year freedom from subsequent treatment failure and overall survival (OS) was 80.1% (95% CI, 69.2-92.6%) and 88.5% (95% CI, 79.5-98.6%), respectively. Inadequate response to salvage systemic therapy (p = 0.048) and male sex (p = 0.049) were significantly associated with LF after salvage RT.
rrHL is responsive to salvage RT, with low LF rates after moderate doses. OS is excellent, despite refractory disease. Initial salvage therapy response predicts subsequent LF.
对于经历疾病进展或复发(15%)的霍奇金淋巴瘤(HL)儿科患者,使用放疗(RT)存在争议。我们报告了接受根治性 RT 治疗的难治性/复发性 HL(rrHL)儿科患者的治疗模式和结局。
在我们的机构中,确定了 46 例接受挽救性 RT 治疗的 rrHL 患者。所有患者均接受了风险适应、基于反应的一线治疗,并接受了细胞减灭方案治疗,随后在失败部位进行 RT,是否联合自体造血细胞移植(AHCT)。在挽救性 RT 后估计局部失败(LF)和生存的累积发生率(CIN),并通过回归模型确定挽救性 RT 后 LF 的预测因素。
RT 作为一线治疗的一部分在 70%的患者中进行,在 13%的患者中因早期反应评估而被省略,在 17%的患者中因原发性进展而被推迟。20%的患者省略了 AHCT。初始和挽救性剂量/部位的中位数分别为 25.5Gy 和 30.6Gy。8 例患者出现进展。2 例患者死于无进展(从挽救性 RT 开始的中位随访时间为 3.8 年)。挽救性 RT 后 LF 的 5 年 CIN 为 17.7%(95%CI,8.2-30.2%)。挽救性 RT 后无后续治疗失败和总生存(OS)的 5 年率分别为 80.1%(95%CI,69.2-92.6%)和 88.5%(95%CI,79.5-98.6%)。挽救性全身治疗反应不足(p=0.048)和男性(p=0.049)与挽救性 RT 后 LF 显著相关。
rrHL 对挽救性 RT 有反应,中等剂量后 LF 率较低。尽管疾病难治,但 OS 非常好。初始挽救性治疗反应预测随后的 LF。